机构:[1]National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China[2]Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK[3]Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China深圳市第二人民医院深圳市康宁医院深圳医学信息中心[4]Department of Haematology, Qilu Hospital, Shandong University, Jinan, China[5]Department of Haematology, Guangdong Provincial People's Hospital, Guangzhou, China广东省人民医院[6]Department of Haematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, China[7]Department of Haematology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China浙江大学医学院附属第一医院[8]Center of Haematology, The First Affiliated Hospital of Nanchang University, Nanchang, China[9]The First Affiliated Hospital of Kunming Medical University, Kunming, China昆明医科大学附属第一医院[10]The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China[11]Fujian Medical University Union Hospital, Fuzhou, China[12]Xi'an International Medical Center Hospital, Xi'an, China[13]Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China中国医科大学附属盛京医院中国医科大学盛京医院[14]Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China大连医科大学附属第一医院[15]Department of Hematology, Beijing Hospital, Beijing, China[16]Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing, China[17]Department of Haematology, Nanfang Hospital, Southern Medical University, Guangzhou, China[18]Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China[19]Department of Haematology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院[20]Department of Haematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China四川省人民医院[21]Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China四川省人民医院[22]The Second Affiliated Hospital of Fujian Medical University, Fujian, China[23]Department of Haematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China[24]Department of Haematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China河南省肿瘤医院[25]Department of Haematology, Institute of Haematology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[26]Department of Haematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院[27]The First Affiliated Hospital, Harbin Medical University, Harbin, China[28]Hematology Department, The General Hospital of Western Theater Command, PLA, Chengdu, China[29]First Hospital of Shangxi Medical University, Shangxi, China[30]Dept. of Hematology, The Second Hospital Affiliated to Kunming medical university, Kunming, China[31]National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China[32]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[33]Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China[34]Hainan General Hospital, Hainan, China[35]National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China[36]First Hospital of Jilin University, Jilin, China[37]The Second Hospital of Hebei Medical University, Shijiazhuang, China[38]Anyang District Hospital, Puyang, China[39]Shenzhen Hospital of Southern Medical University, Shenzhen, China南方医科大学深圳医院深圳医学信息中心[40]Department of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China[41]Collaborative Innovation Center of Haematology, Soochow University, Suzhou, China[42]Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China[43]Research Unit of Key Technique for Diagnosis and Treatments of Haematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China
第一作者机构:[1]National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China
共同第一作者:
通讯作者:
通讯机构:[1]National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China[41]Collaborative Innovation Center of Haematology, Soochow University, Suzhou, China[42]Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China[43]Research Unit of Key Technique for Diagnosis and Treatments of Haematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China[*1]Peking University People's Hospital, Peking University Institute of Haematology, National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhimen South St. Beijing 100044, China.[*2]Peking University People's Hospital, Peking University Institute of Haematology, National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, No. 11 Xizhimen South St., Beijing 100044, China.
推荐引用方式(GB/T 7714):
Yang Sen,Zhang Xiaoshuai,Gale Robert Peter,et al.Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase[J].AMERICAN JOURNAL OF HEMATOLOGY.2023,98(7):E183-E186.doi:10.1002/ajh.26943.
APA:
Yang Sen,Zhang Xiaoshuai,Gale Robert Peter,Du Xin,Chen Chun-Yan...&Jiang Qian.(2023).Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase.AMERICAN JOURNAL OF HEMATOLOGY,98,(7)
MLA:
Yang Sen,et al."Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase".AMERICAN JOURNAL OF HEMATOLOGY 98..7(2023):E183-E186